Announcement
10.02.2012
NeuroSearch A/S (NEUR) hereby updates the company's financial calendar for 2012 as a consequence of the changed date for the Annual General Meeting:
Financial calendar for 2012
28 February 2012 Annual Report 2011 10 April 2012 Annual General Meeting 25 April 2012 Interim report for the first three months of 2012 30 August 2012 Interim report for the first six months of 2012 15 November 2012 Interim report for the first nine months of 2012
Patrik Dahlen CEO
Contact person René Schneider, EVP & CFO, telephone: +45 4460 8700 or +45 2911 2097
About NeuroSearch NeuroSearch A/S (NEUR) is a European-based biopharmaceutical company listed on NASDAQ OMX Copenhagen A/S and specialising in central nervous system (CNS) disorders. The vision is to develop NeuroSearch into a profitable specialty pharmaceutical company. The strategy is to complete the development and subsequently to market Huntexil®, a unique drug in clinical Phase III for the treatment of the motor symptoms of Huntington's disease. As a consequence of the restructuring of NeuroSearch that was announced 27 September 2011, the company also has a portfolio of assets for outlicensing or divestment.
Attachment:
https://newsclient.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=377876
NeuroSearch A/S (NEUR) hereby updates the company's financial calendar for 2012 as a consequence of the changed date for the Annual General Meeting:
Financial calendar for 2012
28 February 2012 Annual Report 2011 10 April 2012 Annual General Meeting 25 April 2012 Interim report for the first three months of 2012 30 August 2012 Interim report for the first six months of 2012 15 November 2012 Interim report for the first nine months of 2012
Patrik Dahlen CEO
Contact person René Schneider, EVP & CFO, telephone: +45 4460 8700 or +45 2911 2097
About NeuroSearch NeuroSearch A/S (NEUR) is a European-based biopharmaceutical company listed on NASDAQ OMX Copenhagen A/S and specialising in central nervous system (CNS) disorders. The vision is to develop NeuroSearch into a profitable specialty pharmaceutical company. The strategy is to complete the development and subsequently to market Huntexil®, a unique drug in clinical Phase III for the treatment of the motor symptoms of Huntington's disease. As a consequence of the restructuring of NeuroSearch that was announced 27 September 2011, the company also has a portfolio of assets for outlicensing or divestment.
Attachment:
https://newsclient.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=377876
© 2012 GlobeNewswire
